Methods of treating HIV-1 infection utilizing broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibodies
The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies may be characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.
1. A method of passive immunization or treating an HIV-1 infection comprising the step of administering to a patient in need thereof, an effective amount of a pharmaceutical composition comprising a therapeutically effective amount of a non-naturally occurring PGT-121 monoclonal antibody or antigen binding portion thereof comprising (a) a light chain variable region comprising three complementarity determining regions comprising the amino acid sequences of SEQ ID NOS: 150, 151, and 152 and (b) a heavy chain variable region comprising three complementarity determining regions comprising the amino acid sequences of SEQ ID NOS: 143, 144, and 145.
2. A method of passive immunization or treating an HIV-1 infection comprising the step of administering to a patient in need thereof, an effective amount of a pharmaceutical composition comprising a therapeutically effective amount of a non-naturally occurring PGT-121 monoclonal antibody or antigen binding portion thereof comprising (a) a light chain variable region comprising three complementarity determining regions comprising the amino acid sequences of SEQ ID NOS: 150, 151, and 152 and (b) a heavy chain variable region comprising three complementarity determining regions comprising the amino acid sequences of SEQ ID NOS: 90, 265, and 143.
3. The method of claim 1 , wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 79 and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 149.
4. The method of claim 2 , wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 79 and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 149.
5. The method of claim 1 , wherein the antibody has a heavy chain sequence comprising the amino acid sequence of SEQ ID NO: 66 and a light chain sequence comprising the amino acid sequence of SEQ ID NO: 148.
6. The method of claim 2 , wherein the antibody has a heavy chain sequence comprising the amino acid sequence of SEQ ID NO: 66 and a light chain sequence comprising the amino acid sequence of SEQ ID NO: 148.
7. The method of claim 1 , wherein the passive immunization or treating an HIV-1 infection comprises inhibiting HIV-1 viral replication.
8. The method of claim 2 , wherein the passive immunization or treating an HIV-1 infection comprises inhibiting HIV-1 viral replication.
9. The method of claim 1 , wherein the PGT-121 monoclonal antibody or antigen binding portion thereof is encoded by an immortalized B cell clone.
10. The method of claim 2 , wherein the PGT-121 monoclonal antibody or antigen binding portion thereof is encoded by an immortalized B cell clone.
11. The method of claim 1 , wherein the composition further comprises a pharmaceutically acceptable carrier.
12. The method of claim 2 , wherein the composition further comprises a pharmaceutically acceptable carrier.
13. The method of claim 11 , wherein the pharmaceutically acceptable carrier is a buffer, antioxidant, a 10 residue or less polypeptide, a protein, a hydrophilic polymer, an amino acid, a sugar, carbohydrate; a chelating agent, a sugar alcohol, a salt-forming counterion, a nonionic surfactant.
14. The method of claim 13 , wherein the buffer is an acetate, Tris, phosphate, citrate or organic acid; the antioxidant is an ascorbic acid or methionine; the protein is a serum albumin, gelatin or immunoglobulin; the hydrophilic polymer is serum albumin, gelatin, immunoglobulin; the amino acid is glycine, glutamine, asparagine, arginine or lysine; the sugar is a monosaccharide, disaccharide, sucrose, mannitol, trehalose or sorbitol; the carbohydrate is glucose, mannose or dextrin, the chelating agent is EDTA, the sugar alcohol is mannitol or sorbitol; the salt-forming counterion is sodium or the non-ionic surfactant is TWEEN® (polysorbate), polyethylene glycol (PEG) or PLURONICS® (poloxamer).
15. The method of claim 12 , wherein the pharmaceutically acceptable carrier is a buffer, antioxidant, a 10 residue or less polypeptide, a protein, a hydrophilic polymer, an amino acid, a sugar, carbohydrate; a chelating agent, a sugar alcohol, a salt-forming counterion, a nonionic surfactant.
16. The method of claim 15 , wherein the buffer is an acetate, Tris, phosphate, citrate or organic acid; the antioxidant is an ascorbic acid or methionine; the protein is a serum albumin, gelatin or immunoglobulin; the hydrophilic polymer is serum albumin, gelatin, immunoglobulin; the amino acid is glycine, glutamine, asparagine, arginine or lysine; the sugar is a monosaccharide, disaccharide, sucrose, mannitol, trehalose or sorbitol; the carbohydrate is glucose, mannose or dextrin, the chelating agent is EDTA, the sugar alcohol is mannitol or sorbitol; the salt-forming counterion is sodium or the non-ionic surfactant is TWEEN® (polysorbate), polyethylene glycol (PEG) or PLURONICS® (poloxamer).
17. The method of claim 1 , wherein the therapeutically effective amount of a non-naturally occurring PGT-121 monoclonal antibody or antigen binding portion thereof is in a sustained-release preparation.
18. The method of claim 17 , wherein the sustained-release preparation is a semi-permeable matrix of solid hydrophobic polymers containing the antibody.
19. The method of claim 18 , wherein the sustained-released matrix is a polyester, hydrogel, polylactide, copolymer of L-glutamic acid and 7 ethyl-L-glutamate, non-degradable ethylene-vinyl acetate or degradable lactic acid-glycolic acid copolymer.
20. The method of claim 19 , wherein the hydrogel is a poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol) or the degradable lactic acid-glycolic acid copolymer is an injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate or and poly-D-(−)-3-hydroxyburyric acid.
21. The method of claim 2 , wherein the therapeutically effective amount of a non-naturally occurring PGT-121 monoclonal antibody or antigen binding portion thereof is in a sustained-release preparation.
22. The method of claim 21 , wherein the sustained-release preparation is a semi-permeable matrix of solid hydrophobic polymers containing the antibody.
23. The method of claim 22 , wherein the sustained-released matrix is a polyester, hydrogel, polylactide, copolymer of L-glutamic acid and 7 ethyl-L-glutamate, non-degradable ethylene-vinyl acetate or degradable lactic acid-glycolic acid copolymer.
24. The method of claim 23 , wherein the hydrogel is a poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol) or the degradable lactic acid-glycolic acid copolymer is an injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate or and poly-D-(−)-3-hydroxyburyric acid.
25. The method of claim 1 , wherein the patient has contacted a person infected with HIV-1 or who has been exposed to HIV-1.
26. The method of claim 2 , wherein the patient has contacted a person infected with HIV-1 or who has been exposed to HIV-1.
27. The method of claim 1 , wherein the administering is intravenous, intramuscular, intraperitoneal, intracerobrospinal, subcutaneous, intra-articular, intrasynovial, intrathecal, oral, topical, inhalation or parenteral.
28. The method of claim 2 , wherein the administering is intravenous, intramuscular, intraperitoneal, intracerobrospinal, subcutaneous, intra-articular, intrasynovial, intrathecal, oral, topical, inhalation or parenteral.
29. The method of claim 1 , wherein the therapeutically effective amount is about 0.1 mg/kg to about 50 mg/kg of patient body weight.
30. The method of claim 29 , wherein the administering is by separate administration or by continuous infusion.
31. The method of claim 2 , wherein the therapeutically effective amount is about 0.1 mg/kg to about 50 mg/kg of patient body weight.
32. The method of claim 31 , wherein the administering is by separate administration or by continuous infusion.
33. The method of claim 1 , wherein the administering is in combination with another therapeutic regimen.
34. The method of claim 33 , wherein the combination is co-administration with a separate formulation or a single formulation or consecutive administration.
35. The method of claim 33 , wherein the combination results in a synergistic therapeutic effect.
36. The method of claim 33 , wherein the combination comprises an immunoconjugate comprising the antibody or antigen binding portion thereof conjugated with a cytotoxic agent.
37. The method of claim 36 , wherein the cytotoxic agent is a maytansinoid, calicheamicin, ribonuclease or DNA endonuclease.
38. The method of claim 33 , wherein the combination comprises another antibody directed against another antigen associated with the infectious agent.
39. The method of claim 2 , wherein the administering is in combination with another therapeutic regimen.
40. The method of claim 39 , wherein the combination is co-administration with a separate formulation or a single formulation or consecutive administration.
41. The method of claim 39 , wherein the combination results in a synergistic therapeutic effect.
42. The method of claim 39 , wherein the combination comprises an immunoconjugate comprising the antibody or antigen binding portion thereof conjugated with a cytotoxic agent.
43. The method of claim 42 , wherein the cytotoxic agent is a maytansinoid, calicheamicin, ribonuclease or DNA endonuclease.
44. The method of claim 39 , wherein the combination comprises another antibody directed against another antigen associated with the infectious agent.